AbbVie Inc. (BCBA:ABBV)

Argentina flag Argentina · Delayed Price · Currency is ARS
26,700
-25 (-0.09%)
Aug 4, 2025, 4:58 PM BRT
-0.09%
Market Cap470.01T
Revenue (ttm)69.51T
Net Income (ttm)4.44T
Shares Outn/a
EPS (ttm)2,502.76
PE Ratio105.94
Forward PE14.88
Dividend534.09 (2.00%)
Ex-Dividend DateJul 15, 2025
Volume1,085
Average Volume1,318
Open26,600
Previous Close26,725
Day's Range25,250 - 26,875
52-Week Range18,325 - 27,925
Betan/a
RSI74.08
Earnings DateJul 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Sector Healthcare
Founded 2012
Employees 55,000
Stock Exchange Buenos Aires Stock Exchange
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD Financial Statements

News

There is no news available yet.